通脉降脂口服液和洛伐他汀对动脉粥样硬化患者血脂生化指标影响的对比研究  

Comparative study on the effect of tongmai jiangzhi oral solution and lovastatin on blood lipid and biochemical index in patients with atherosclerosis

作　　者：沈晓君[1] 孙婉萍[2] 王玲[3] 

机构地区：[1]河南中医学院病理教研室,河南省郑州市450003 [2]郑州铁路职业技术学院医学院妇幼卫生系,河南省郑州市450052 [3]郑州大学公共卫生学院营养与食品卫生教研室,河南省郑州市450052

出　　处：《中国临床康复》2004年第27期5888-5889,共2页Chinese Journal of Clinical Rehabilitation

基　　金：郑州铁路局科委资助项目(02W30)~~

摘　　要：目的:观察通脉降脂口服液、洛伐他汀对动脉粥样硬化(atherosclerosis,AS)患者血脂、血清血小板α颗粒膜蛋白-140(plateletalphaparticlemembraneprotein,GMP-140)、血管性假血友病因子(vonwillebrandfac-tor,vWF)及肿瘤坏死因子α(tumornecrosisfactor-α,TNF-α)水平的影响,比较二者的差异。方法:病例为郑州铁路中心医院和河南中医学院附属医院门诊就诊的动脉粥样硬化患者,其中33例患者口服通脉降脂口服液治疗(治疗组)、30例口服洛伐他汀治疗(对照组),检测两组患者治疗前后血脂(酶法)、血清GMP-140、vWF及TNF-α(ELISA法)水平。结果:治疗组治疗后血清总胆固醇犤(5.65±0.69)mmol/L犦、三酰甘油犤(2.05±0.70)mmol/L犦、低密度脂蛋白胆固醇犤(3.70±0.72)mmol/L犦、载脂蛋白B-100犤(1.11±0.27)g/L犦、GMP-140犤(19.03±6.09)μg/L犦、vWF犤(135.61±36.55)%犦、TNF-α水平犤(52.64±13.35)ng/L犦显著下降,高密度脂蛋白胆固醇水平犤(1.16±0.32)mmol/L犦显著升高,与治疗前比较,差异有显著性意义(t=2.16～3.04,P<0.05～0.01);调脂疗效与对照组比较除高密度脂蛋白胆固醇(t=2.037,P<0.05)外差异均无显著性意义(P>0.05);两组血清载脂蛋白A-I水平与治疗前比较差异无显著性意义(P>0.05);AIM:To observe the therapeutic effects of tongmai jiangzhi oral solution and lovastatin on atherosclerosis patients by testing blood lipid,platelet alpha particle membrane protein(GMP 140),von willibrand factor(vWF),and tumor necrosis factor alpha(TNF α)levels.Compare with the differences of the two. METHODS:Patients were involved from the atherosclerosis patients being treated in Zhengzhou Railway Central Hospital and Clinic of Henan College of Traditional Chinese Medicine.Thirty three atherosclerosis patients were treated with tongmai jiangzhi(treat group) and thirty were treated with lovastatin(control group).Blood was drawn before and after treatment.Total blood lipids were measured by enzymatic assay.Serum GMP 140,vWF,and TNF αwere measured by ELISA. RESULTS:After tongmai jiangzhi treatment,serum total cholesterol(TC)[(5.65±0.69)mmol/L],triacylglycerol(TG)[(2.05±0.07)mmol/L],low density lipoprotein cholesterol[(3.70±0.72)]mmol/L,apolipoprotein B 100(ApoB 100)[(1.11±0.27)g/L],GMP 140[(19.03±6.09)μg/L],vWF[(135.61±36.55)%],TNF α[(52.64±13.35)ng/L] decreased significantly and high density lipoprotein cholesterol(HDL C)[(1.16±0.320)mmol/L] increased significantly(t=2.16 to 3.04,P< 0.05 to 0.01).There was no significant difference about the level of lipoprotein except serum HDL C(t=2.037,P < 0.05) comparing with control group(P >05).There was no significant difference(P >0.05)between the two treatments of the serum HDL C and GMP 140 levels in control group.There was also no statistic difference between the two treatments on serum ApoA I(P >0.05). CONCLUSION:Both of tongmai jiangzhi and lovastatin have good therapeutic effect on lowering serum TC and TG,which could improve the vessel endothelium function and inhibit inflammation of atherosclerosis plaque.However,tongmai jiangzhi has better effect for increasing HDL C,inhibiting activating of platelet,and reversing disturbance of blood clotting of atherosclerosis patients than that of lovastatin.

关 键 词：动脉硬化/药物疗法 降血脂药 中药方剂学 洛伐他汀 动脉硬化 von WILLEBRAND因子 肿瘤坏死因子 

分 类 号：R543.5[医药卫生—心血管疾病]